Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib malate in EGFR T790M-positive advanced NSCLC (Phase II, single-arm)
CTR20161018Phase 2Active
- Sponsor
- ACEA Pharmaceuticals
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abivertinib in non-small cell lung cancer (NSCLC), sponsored by ACEA Pharmaceuticals. Started Dec 2016; status: active.
02
Drugs
abivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20161018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20161018.